EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|November 15, 2002
Hair Loss Insights
Paris - Results from a series of studies conducted at the Skin Research Laboratory of the Technion-Israel Institute of Technology are providing important insights about the pathogenesis of alopecia areata and a basis for exploring new immunomodulating therapies for the disorder.
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
2
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
3
Tilrekimig Phase 2 Data Show EASI 75 Gains in Atopic Dermatitis
4
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
5